BioXcel Therapeutics to Present BXCL701 Clinical Data at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting
Encouraging signals of activity in difficult-to-treat tumors observed in both ongoing trials with BXCL701 and pembrolizumab (KEYTRUDA®) NEW HAVEN, Conn.,...